Medicines in Development for Antimicrobial Resistance (AMR) 2021 Report

  03 May 2021

As the world confronts the COVID-19 public health crisis, now more than ever is the time to consider preparedness for a growing public health threat: antimicrobial resistance (AMR). AMR is a natural process that occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that make the medicines used to treat the infections they cause ineffective. Therefore, the more we use such medicines, the more resistance we may create. This means a robust and sustained pipeline of new and novel antimicrobial medicines is critical to ensure that new innovations and interventions can keep pace with these evolving pathogens.

Further reading: PhRMA
Author(s): PhRMA
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!